Suzlon Energy – Hansen Stake Sale – Relief for Now

The Hansen stake sale at GBp95/ share fetches suboptimal value even though it may have helped bypass the stalemate on strategic sale process. We highlight a sharp decline in Hansen’s share price since the announcement of a secondary placement by Suzlon.

The transaction implies that Suzlon did not see the strategic sale of Hansen materializing in the near future and strategic buyers were not interested at the expected price. A sharp decline in Hansen to GBp100 from GBp140 appears to reflect the market’s wariness at the lack of interest from strategic buyers at the expected price, hence the much lower valuation.

The value of the placing is about GBP224 mn (about Rs17 bn). This is about 14% of the current net debt of Suzlon’s wind business. We believe the Hansen sale would not provide any valuation upside as we were attributing a higher valuation to Hansen but this may help partially restore the balance sheet and customer confidence. Suzlon would eventually sell the remaining 26% stake as well.

Surprise of 2010: A market consolidation – Merrill

Breaking NewsThe year 2009 has turned out to be a big surprise. It is on track to be the best year for markets
since 1991.Year wise returns in Indian Equities between 1991 and 2009 [ 1991 and 2009 are Manomohan Magic Years ]

The year 2010 is expected to be a year of consolidation rather than the “boom-bust” years in the past. The last time we ended a year with a single digit move (either positive or negative) in the market was in (more…)

MidCap Stocks for Long Term – Part II

Edelweiss Research has initiated coverage on few growth oriented MidCaps. You must read Part-1 of the coverage here. Here is the second set of Stocks recommendation in the MidCap space.

Infotech Enterprises:
Infotech Enterprises (IEL) has developed a unique positioning in the engineering services space.One of the key positives during the recent results is the scale up of revenues from the top 10 clients. Continuous expansion in services portfolio (more…)

MidCap Stock Picks -1

Edelweiss has some favorite picks in the MidCap space where it expects an improvement in top line to drive strong EBITDA growth as revenue growth outpaces costs. Stocks with high degree of operating leverage. Edelweiss’ conviction is that these stocks have a high probability of surprising on the upside over the next 1-3 years.

This is Part 1 of the Coverage and here are the stocks and brief excerpts / justification them being picked up.

AUROBINDO PHARMA:
Strategic alliance with Pfizer (PFE) for 80 products and 218 SKUs across multiple markets adds strategic depth and long-term value. Regulated sales are likely to post 38% CAGR in FY09-11E, to INR 13 bn, as ARBP is poised to benefit from current scale of filings. Expect an EPS of Rs 90 and 118 for FY10 & FY11. Maintain BUY (more…)

Aban Offshore – Back to Growth

The Capital restructuring and the award of long-term contracts at premium dayrates have helped Aban tide over its near-term cash shortfall. Aban has raised US$150 mn through issue of 5.7 mn shares at Rs1,224/share. This amount will primarily be used to redeem the outstanding bonds of NOK1 bn (US$150 mn) due in Dec’09, which were issued by its Norwegian subsidiary Sinvest.

The deployment of four of its jackup rigs at better-than-market rates has significantly improved near-term revenue and cash flow visibility for Aban. Management indicates that it is in an advanced stage of negotiation for the (more…)

1 92 93 94 95 96 480